Moderna, Inc. (NASDAQ:MRNA)

Monday, August 21, 2017 | Web News
MRNA $MRNAD ($2.95) announced that Windlas Healthcare has agreed to invest $2 million in working capital to support MRNA’s manufacturing initiatives...
Wednesday, August 2, 2017 | Web News
MRNA ($0.33) - Marina announced this morning a 1-10 reverse split in anticipation of an uplist to the NASDAQ. The company’...
Thursday, July 20, 2017 | Web News
MRNA ($0.37) announced a license agreement with Oncotelic, Inc for the Company’s SMARTICLES platform for the delivery of antisense DNA therapeutics....
See All Research...
Thursday, February 19, 2015, 10:30 AM
Marina Biotech: One Man's Trash is Another Man's Treasure
Tuesday, November 25, 2014, 9:45 AM
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
See All Articles and Reports...
Marina Biotech, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of oligonucleotide therapies based on RNA interference (RNAi) and RNA (mRNA) transcriptions. Its pipeline includes a clinical program in Familial Adenomatous Polyposis, which is a precancerous syndrome; and two preclinical programs in malignant ascites and bladder cancer. The company was formerly known as MDRNA, Inc. and changed its name to Marina Biotech, Inc. in July 2010. Marina Biotech, Inc. was founded in 1983 and is headquartered in Bothell, Washington.

Web site: http://www.marinabio.com

Last updated March 16, 2012


Market Data powered by QuoteMedia. Terms of Use